JP2006514681A - エポチロンdの投与方法 - Google Patents

エポチロンdの投与方法 Download PDF

Info

Publication number
JP2006514681A
JP2006514681A JP2004572190A JP2004572190A JP2006514681A JP 2006514681 A JP2006514681 A JP 2006514681A JP 2004572190 A JP2004572190 A JP 2004572190A JP 2004572190 A JP2004572190 A JP 2004572190A JP 2006514681 A JP2006514681 A JP 2006514681A
Authority
JP
Japan
Prior art keywords
epothilone
subject
administering
intravenous infusion
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004572190A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514681A5 (cg-RX-API-DMAC7.html
Inventor
ジュニア ロバート ジー ジョンソン
マイケル シェリル
アリソン ハンナ
Original Assignee
コーザン バイオサイエンシス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーザン バイオサイエンシス インコーポレイテッド filed Critical コーザン バイオサイエンシス インコーポレイテッド
Publication of JP2006514681A publication Critical patent/JP2006514681A/ja
Publication of JP2006514681A5 publication Critical patent/JP2006514681A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2004572190A 2002-05-20 2003-05-20 エポチロンdの投与方法 Pending JP2006514681A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38216602P 2002-05-20 2002-05-20
PCT/US2003/017921 WO2004103267A2 (en) 2002-05-20 2003-05-20 Methods to administer epothilone d

Publications (2)

Publication Number Publication Date
JP2006514681A true JP2006514681A (ja) 2006-05-11
JP2006514681A5 JP2006514681A5 (cg-RX-API-DMAC7.html) 2006-07-13

Family

ID=33476529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004572190A Pending JP2006514681A (ja) 2002-05-20 2003-05-20 エポチロンdの投与方法

Country Status (7)

Country Link
US (1) US20040072882A1 (cg-RX-API-DMAC7.html)
EP (1) EP1575556A2 (cg-RX-API-DMAC7.html)
JP (1) JP2006514681A (cg-RX-API-DMAC7.html)
KR (1) KR20050043796A (cg-RX-API-DMAC7.html)
CN (1) CN101389334A (cg-RX-API-DMAC7.html)
AU (1) AU2003296878A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004103267A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) * 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CN1870995A (zh) * 2003-09-02 2006-11-29 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US20050171167A1 (en) * 2003-11-04 2005-08-04 Haby Thomas A. Process and formulation containing epothilones and analogs thereof
US20050215604A1 (en) * 2004-03-26 2005-09-29 Kosan Biosciences, Inc. Combination therapies with epothilones and carboplatin
EP2634252B1 (en) 2005-02-11 2018-12-19 University of Southern California Method of expressing proteins with disulfide bridges
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
KR101604864B1 (ko) * 2008-04-25 2016-03-18 에이에스엠 인터내셔널 엔.브이. 텔루르와 셀렌 박막의 원자층 증착을 위한 전구체의 합성과 그 용도
US8802394B2 (en) 2008-11-13 2014-08-12 Radu O. Minea Method of expressing proteins with disulfide bridges with enhanced yields and activity
WO2011056519A2 (en) 2009-10-26 2011-05-12 Asm International N.V. Synthesis and use of precursors for ald of group va element containing thin films
CA2927832C (en) 2010-05-18 2021-03-23 Cerulean Pharma Inc. Cyclodextrin-containing polymer-therapeutic agent conjugates and their use

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507930A (ja) * 1996-03-12 2000-06-27 ピージー―ティーエックスエル・カンパニー・エル・ピー 水溶性パクリタキセルプロドラッグ
WO2000061142A1 (en) * 1999-04-14 2000-10-19 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
WO2001064650A2 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
WO2001083800A2 (en) * 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Heterologous production of polyketides
JP2001525324A (ja) * 1997-12-04 2001-12-11 ブリストル−マイヤーズ スクイブ カンパニー オキシラニルエポチロン化合物のオレフィン性エポチロン化合物への還元法
WO2002008440A2 (en) * 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones
JP2002504346A (ja) * 1998-02-19 2002-02-12 ノバルティス アクチエンゲゼルシャフト 細胞増殖抑制剤の発酵生産方法及びそれらの結晶体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) * 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
CN100381566C (zh) * 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000507930A (ja) * 1996-03-12 2000-06-27 ピージー―ティーエックスエル・カンパニー・エル・ピー 水溶性パクリタキセルプロドラッグ
JP2001525324A (ja) * 1997-12-04 2001-12-11 ブリストル−マイヤーズ スクイブ カンパニー オキシラニルエポチロン化合物のオレフィン性エポチロン化合物への還元法
JP2002504346A (ja) * 1998-02-19 2002-02-12 ノバルティス アクチエンゲゼルシャフト 細胞増殖抑制剤の発酵生産方法及びそれらの結晶体
WO2000061142A1 (en) * 1999-04-14 2000-10-19 Dana-Farber Cancer Institute, Inc. Method and composition for the treatment of cancer
WO2001064650A2 (en) * 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
WO2001083800A2 (en) * 2000-04-28 2001-11-08 Kosan Biosciences, Inc. Heterologous production of polyketides
WO2002008440A2 (en) * 2000-07-25 2002-01-31 Kosan Biosciences, Inc. Fermentation process for epothilones

Also Published As

Publication number Publication date
WO2004103267A2 (en) 2004-12-02
WO2004103267A3 (en) 2008-11-27
AU2003296878A8 (en) 2009-01-08
KR20050043796A (ko) 2005-05-11
AU2003296878A1 (en) 2004-12-13
EP1575556A2 (en) 2005-09-21
US20040072882A1 (en) 2004-04-15
CN101389334A (zh) 2009-03-18

Similar Documents

Publication Publication Date Title
Stuurman et al. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement
Mani et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors
Mayer et al. Chemotherapy for metastatic breast cancer
Secord et al. A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer
Larkin et al. Epothilones in the treatment of cancer
Peterson et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models
Gadgeel et al. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design
Fracasso et al. Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies
FR2775187A1 (fr) Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US20040072882A1 (en) Methods to administer epothilone D
Mukai et al. Phase I study of NK105, a nanomicellar paclitaxel formulation, administered on a weekly schedule in patients with solid tumors
US11291681B2 (en) Method for treating fibrotic liver tissue using Cl-IB-MECA
Peyrl et al. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged< 3 years
Shimizu et al. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors
KR20080081249A (ko) 17-aag 또는 17-ag, 또는 이 중 어느 하나의 전구약물과 her2 억제제의 조합을 사용하여 유방암을치료하는 방법
JP2022515249A (ja) 癌の治療におけるドセタキセルの長期使用
Lockhart et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors
Zhang et al. Phase I clinical and pharmacokinetic study of UTD1, a genetically engineered epothilone analog in patients with advanced solid tumors
Kunz et al. Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors
Monk et al. A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors
Hensley et al. A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors
Giaccone et al. Preliminary results of two dose-finding studies of Paclitaxel (Taxol) and carboplatin in Non-small Cell Lung and Ovarian
McEntee et al. Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs
US11911374B2 (en) Methods and uses for treating cancer
US20230302034A1 (en) Methods And Compositions For Cancer Therapies That Include Delivery Of Halogenated Thymidines And Thymidine Phosphorylase Inhibitors In Combination With Radiation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060522

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060522

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100419